Société de Therapeutique Marocaine S.A.

CBSE:SOT Stok Raporu

Piyasa değeri: د.م6.8b

Société de Therapeutique Marocaine Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Société de Therapeutique Marocaine's EPS is expected to grow by 7.5% per annum.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

7.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi19.4%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

None

Son güncellemen/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

CBSE:SOT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (MAD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
6/30/20242,63028125143N/A
3/31/20242,5582724122N/A
12/31/20232,486263-18100N/A
9/30/20232,41126221121N/A
6/30/20232,33626060143N/A
3/31/20232,31926473150N/A
12/31/20222,30226786156N/A
9/30/20222,268286129197N/A
6/30/20222,233306173237N/A
3/31/20222,145293219282N/A
12/31/20212,056279265328N/A
9/30/20211,998264199258N/A
6/30/20211,940249133189N/A
3/31/20211,86924084141N/A
12/31/20201,7982303594N/A
9/30/20201,737233N/AN/AN/A
6/30/20201,675235N/AN/AN/A
3/31/20201,680227N/AN/AN/A
12/31/20191,686220155227N/A
9/30/20191,647173N/AN/AN/A
6/30/20191,667196N/AN/AN/A
3/31/20191,629207N/AN/AN/A
12/31/20181,561182111163N/A
9/30/20181,544208N/AN/AN/A
6/30/20181,497198N/AN/AN/A
3/31/20181,456174N/AN/AN/A
12/31/20171,415150N/A193N/A
9/30/20171,400153N/AN/AN/A
6/30/20171,386155N/AN/AN/A
3/31/20171,356152N/AN/AN/A
12/31/20161,326149N/A190N/A
9/30/20161,261135N/AN/AN/A
6/30/20161,195121N/AN/AN/A
3/31/20161,175119N/AN/AN/A
12/31/20151,156118N/A161N/A
9/30/20151,155115N/AN/AN/A
6/30/20151,155113N/AN/AN/A
3/31/20151,138102N/AN/AN/A
12/31/20141,12292N/A137N/A
9/30/20141,12595N/AN/AN/A
6/30/20141,12997N/AN/AN/A
3/31/20141,124107N/AN/AN/A
12/31/20131,119117N/A159N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if SOT's forecast earnings growth is above the savings rate (14.5%).

Kazançlar ve Piyasa: Insufficient data to determine if SOT's earnings are forecast to grow faster than the MA market

Yüksek Büyüme Kazançları: Insufficient data to determine if SOT's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if SOT's revenue is forecast to grow faster than the MA market.

Yüksek Büyüme Geliri: Insufficient data to determine if SOT's revenue is forecast to grow faster than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if SOT's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin